These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15844623)

  • 1. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.
    Zhang MY; Choudhry V; Xiao X; Dimitrov DS
    Curr Opin Mol Ther; 2005 Apr; 7(2):151-6. PubMed ID: 15844623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
    Tsunetsugu-Yokota Y; Ohnishi K; Takemori T
    Rev Med Virol; 2006; 16(2):117-31. PubMed ID: 16518829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
    Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
    J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
    Coughlin M; Lou G; Martinez O; Masterman SK; Olsen OA; Moksa AA; Farzan M; Babcook JS; Prabhakar BS
    Virology; 2007 Apr; 361(1):93-102. PubMed ID: 17161858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
    Zhu Z; Chakraborti S; He Y; Roberts A; Sheahan T; Xiao X; Hensley LE; Prabakaran P; Rockx B; Sidorov IA; Corti D; Vogel L; Feng Y; Kim JO; Wang LF; Baric R; Lanzavecchia A; Curtis KM; Nabel GJ; Subbarao K; Jiang S; Dimitrov DS
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12123-8. PubMed ID: 17620608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
    Suresh MR; Bhatnagar PK; Das D
    J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
    Miyoshi-Akiyama T; Ishida I; Fukushi M; Yamaguchi K; Matsuoka Y; Ishihara T; Tsukahara M; Hatakeyama S; Itoh N; Morisawa A; Yoshinaka Y; Yamamoto N; Lianfeng Z; Chuan Q; Kirikae T; Sasazuki T
    J Infect Dis; 2011 Jun; 203(11):1574-81. PubMed ID: 21592986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.
    Rockx B; Donaldson E; Frieman M; Sheahan T; Corti D; Lanzavecchia A; Baric RS
    J Infect Dis; 2010 Mar; 201(6):946-55. PubMed ID: 20144042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
    Coughlin MM; Prabhakar BS
    Rev Med Virol; 2012 Jan; 22(1):2-17. PubMed ID: 21905149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of monoclonal antibodies against SARS coronavirus.
    Ohnishi K
    Methods Mol Biol; 2008; 454():191-203. PubMed ID: 19057876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
    van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
    J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.
    Lip KM; Shen S; Yang X; Keng CT; Zhang A; Oh HL; Li ZH; Hwang LA; Chou CF; Fielding BC; Tan TH; Mayrhofer J; Falkner FG; Fu J; Lim SG; Hong W; Tan YJ
    J Virol; 2006 Jan; 80(2):941-50. PubMed ID: 16378996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.
    Lu B; Tao L; Wang T; Zheng Z; Li B; Chen Z; Huang Y; Hu Q; Wang H
    Clin Vaccine Immunol; 2009 Jan; 16(1):73-7. PubMed ID: 18987164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay.
    Sunwoo HH; Palaniyappan A; Ganguly A; Bhatnagar PK; Das D; El-Kadi AO; Suresh MR
    J Virol Methods; 2013 Jan; 187(1):72-8. PubMed ID: 22995576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.